Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines By Investing.com
Up to date Section 1 dose-escalation information from ARROS-1 and ALKOVE-1 scientific trials proceed to help potential best-in-class profiles for ...